Table 2. Distribution of serum biomarkers and other factors by presence of brain metastases at baseline or development of subsequent brain metastases after baseline.
| Number of Patients | Number with Brain Metastasis | |||
|---|---|---|---|---|
| Biomarker | At Baseline | After Baseline | ||
| Overall | 104 | 26 (25%) | 25 (24%) | |
| CYFRA 21–1 | ||||
| ≤ 3.3 ng/ml | 56 (54%) | 12 | 15 | |
| >3.3 ng/ml | 48 (46%) | 14 | 10 | |
| NSE | ||||
| ≤13 ng/ml | 86 (83%) | 23 | 19 | |
| >13 ng/ml | 18 (17%) | 3 | 6 | |
| ProGRP | ||||
| ≤50 pg/ml | 38 (37%) | 12 | 8 | |
| >50 pg/ml | 9 (9%) | 1 | 2 | |
| Unknown | 57 (55%) | 13 | 15 | |
| SCCL-Ag | ||||
| ≤2.0 ng/ml | 96 (92%) | 25 | 25 | |
| >2.0 ng/ml | 8 (8%) | 1 | 0 | |
| HE4 | ||||
| ≤65 pmol/L | 28 (27%) | 8 | 3 | |
| >65 pmol/L | 76 (73%) | 18 | 22 | |
| TIMP1 | ||||
| >55.5 μg/L | 79 (76%) | 21 | 16 | |
| Unknown | 25 (24%) | 5 | 9 | |